Deutsche Bank Ag\ Exagen Inc. Transaction History

Deutsche Bank Ag\

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.69 - $8.68 $61,019 - $196,897	-22,684 Reduced 30.93%	50,660 $137,000
Q2 2022 Aug 11, 2022	SELL	$4.18 - $7.74 $23,445 - $43,413	-5,609 Reduced 7.1%	73,344 $421,000
Q1 2022 May 13, 2022	SELL	$7.12 - $11.06 $4,684 - $7,277	-658 Reduced 0.83%	78,953 $634,000
Q4 2021 Feb 11, 2022	SELL	$8.97 - $14.08 $1.25 Million - $1.97 Million	-139,588 Reduced 63.68%	79,611 $926,000
Q3 2021 Nov 04, 2021	SELL	$10.25 - $15.21 $887,281 - $1.32 Million	-86,564 Reduced 28.31%	219,199 $2.98 Million
Q2 2021 Aug 11, 2021	BUY	$12.4 - $17.92 $3.75 Million - $5.42 Million	302,685 Added 9833.82%	305,763 $4.58 Million
Q1 2021 May 13, 2021	SELL	$13.9 - $22.0 $4,003 - $6,336	-288 Reduced 8.56%	3,078 $53,000
Q4 2020 Feb 16, 2021	BUY	$11.19 - $16.05 $10,563 - $15,151	944 Added 38.98%	3,366 $44,000
Q3 2020 Nov 12, 2020	BUY	$10.56 - $16.69 $2,365 - $3,738	224 Added 10.19%	2,422 $26,000
Q2 2020 Aug 13, 2020	BUY	$11.0 - $16.7 $12,705 - $19,288	1,155 Added 110.74%	2,198 $27,000
Q1 2020 May 14, 2020	SELL	$12.7 - $25.95 $838 - $1,712	-66 Reduced 5.95%	1,043 $17,000
Q4 2019 Feb 14, 2020	BUY	$12.61 - $28.48 $13,984 - $31,584	1,109 New	1,109 $28,000

6.41M

4.5K

400

Ticker XGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,260,400
Market Cap $89.8M
Description
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.